RESUMEN
Traumatic central nervous system (CNS) injury often causes irreversible impairment, and new alternative therapies for the treatment of CNS injury and sequelae are expected to be developed. Recently, mesenchymal stromal cells (MSCs) have started being used as cell therapy for neurological disorders such as traumatic CNS injury based on their immunomodulatory, neuroprotective, and neurorestorative abilities. Based on the premise of basic research, numerous clinical trials using MSCs for the treatment of traumatic CNS injury have been performed, and the feasibility and efficacy of this therapy have been reported. In this review we aimed to shed light on the characteristics of MSCs and to discuss the basic and clinical research and recent progress in clinical studies using MSCs to treat various traumatic neurological injuries.
Asunto(s)
Células Madre Mesenquimatosas , Traumatismos del Sistema Nervioso , Tratamiento Basado en Trasplante de Células y Tejidos , Sistema Nervioso Central , HumanosAsunto(s)
Epilepsia , Enfermedades del Sistema Nervioso Periférico , Paraplejía Espástica Hereditaria , Ataxia/complicaciones , Ataxia/genética , Cuerpo Calloso/diagnóstico por imagen , Epilepsia/complicaciones , Epilepsia/genética , Humanos , Mutación/genética , Paraplejía/complicaciones , Paraplejía/genética , Enfermedades del Sistema Nervioso Periférico/complicaciones , Paraplejía Espástica Hereditaria/complicaciones , Paraplejía Espástica Hereditaria/genética , Espastina/genéticaRESUMEN
Several studies have shown that mesenchymal stromal/stem cells (MSCs) exert their neuroprotective and neurorestorative efficacy via the secretion of neurotrophic factors. Based on these studies, many clinical trials using MSCs for the treatment of neurological disorders have been conducted, and results regarding their feasibility and efficacy have been reported. The present review aims to highlight the characteristics and basic research regarding the role of MSCs in neurological disease and to discuss the recent progress in clinical trials using MSCs to treat various neurological disorders.
Asunto(s)
Actinas/genética , Mosaicismo , Mutación Missense , Miopatías Nemalínicas/genética , Preescolar , Análisis Mutacional de ADN , Secuenciación de Nucleótidos de Alto Rendimiento , Humanos , Masculino , Músculo Esquelético/patología , Miopatías Nemalínicas/diagnóstico , Miopatías Nemalínicas/patologíaRESUMEN
We report a neonate of severe cytomegalovirus (CMV) infection who presented vomiting, severe thrombocytopenia and thrombotic microangiopathy (TMA). He showed occasional vomiting at 3 weeks of age and visited us with systemic petechiae at 29 days old. Platelet was markedly decreased to 18,000/µL and fragmented red blood cells were increased in the peripheral blood. Intravenous ganciclovir (GCV) administration was started at 35 days old after detection of CMV in the peripheral blood. His normal values of T-cell receptor excision circles (TREC) and signal joint kappa-deleting recombination excision circles (sjKREC) excluded the possibility of severe immunodeficiency. Congenital CMV infection was denied later, when CMV of the dried blood spot obtained for neonatal mass-screening at 4 days old was proved negative. We provided 6-week treatment with no side effect such as myelosuppression. The left hearing abnormality found at first was improved along with other symptoms. GCV seems to be effective and safe for severe neonatal CMV infection.
